Business Context and Reporting Period
This Form 8-K is filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on November 12, 2025. The report addresses a strategic decision by the Board of Directors to wind down and exit the Company's ClearUP business, with completion expected prior to the end of 2025. Following this exit, the Company intends to focus primarily on its biopharma program and the development of its biopharmaceutical product candidates.
Key Financial Metrics
- Exit Costs Incurred: Approximately $347,000 in charges were incurred during the quarter ended September 30, 2025, related to the ClearUP wind-down.
- Projected Additional Costs: The Company expects to incur an additional $20,000 to $50,000 in expenditures through the end of the year.
- Revenue Outlook: The Company expects to generate minimal to no revenue until regulatory approval and commercialization of other product candidates are achieved.
- Liquidity and Debt: The filing text does not provide specific values for total cash, debt, or liquidity ratios.
Material Changes
The primary material change is the strategic exit from the ClearUP business line. This decision results in a shift from a diversified operational model to a singular focus on biopharmaceutical development. Consequently, the Company anticipates a cessation of revenue from the ClearUP segment, leading to minimal overall revenue generation in the near term.
Guidance, Outlook, and Risks
- Management Commentary: The Board determined the wind-down is in the best interest of stockholders following a broader strategic reassessment.
- Forward-Looking Statements: Estimates regarding charges, costs, and revenue are subject to assumptions; actual results may differ materially.
- Risks and Contingencies: The Company may incur unanticipated charges or cash expenditures due to events arising from the wind-down process. Future financial performance is heavily dependent on the successful regulatory approval and commercialization of remaining biopharma candidates.
Investor Verification Checklist
- Verify the exact remaining cash balance and runway given the expectation of minimal revenue.
- Confirm the specific timeline for the completion of the ClearUP wind-down.
- Review the status and development pipeline of the remaining biopharmaceutical product candidates.
- Check for any additional unanticipated costs related to the exit activities not currently contemplated.